Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Arcutis Biotherapeutics, Inc. - Common stock (NQ: ARQT )

14.62 -0.19 (-1.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 Next >
A Glimpse Into The Expert Outlook On Arcutis Biotherapeutics Through 5 Analysts
Via Benzinga
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally
Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter. 
Via Stocktwits
Earnings Scheduled For February 25, 2025
Via Benzinga
4 Analysts Have This To Say About Arcutis Biotherapeutics
Via Benzinga
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025. 
Via Investor's Business Daily
Exposures Product Safety
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews
Via Benzinga
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts
Via Benzinga
Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights
Via Benzinga
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Via Benzinga
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
Via Benzinga
CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday
Via Benzinga
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
Via Benzinga
Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024
ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
7 Biotech Stocks to Keep on Your Clinical Radar
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years
FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged six and older. Zoryve provides a steroid-free treatment option. Significant... 
Via Benzinga
Exposures Product Safety
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
The 7 Best Under $10 Stocks to Buy in July 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now. 
Via InvestorPlace
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Have $5-10? 7 Affordable Stocks That Are About to Breakout.
These stocks are already showing gains this year, but they are all still affordable stocks ready to breakout. 
Via InvestorPlace
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning! 
Via InvestorPlace
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.